EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture

Thrombosis and Haemostasis

Volumn 95, Issue 1, 2006, Pages 151-158

  Schmidt, Roland ^a   Redecke, Vanessa ^a   Breitfeld, Yoshi ^a   Wantia, Nina ^a   Miethke, Thomas ^a   Massberg, Stephen ^a   Fischel, Sina ^a   Neuman, Franz Josef ^a,c   Schömig, Albert ^a   May, Andreas E ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

C. pneumoniae; EMMPRIN; MMPs; Monocytes; Plaque rupture

Indexed keywords

CD147 ANTIGEN; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 60; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMIN; UROKINASE RECEPTOR;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DEGRADATION KINETICS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; HUMAN CELL; MONOCYTE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SUPERNATANT;

ANTIGENS, CD147; ATHEROSCLEROSIS; BACTERIAL PROTEINS; CELL LINE; CELL MOVEMENT; CHAPERONIN 60; CHLAMYDOPHILA PNEUMONIAE; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PARACRINE COMMUNICATION; PROTEOGLYCANS; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RUPTURE, SPONTANEOUS;

EID: 33645553116     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1007/3-540-31304-4_12     Document Type: Article

References (40)

1. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
2. May AE, Neumann FJ, Preissner KT. The relevance of blood cell vessel wall interactions for vascular thrombotic disease. Thromb Haemost 1999; 82: 962-9.
3. Libby P. Current Concepts of the pathogenesis of acute coronary syndromes. Circulation 2002; 104: 365-72.
4. Neumann FJ. Chlamydia pneumoniae-atherosclerosis link: a sound concept in search for clinical relevance. Circulation 2002; 106: 2428-33.
5. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350: 430-6.
6. Maass M, Bartels C, Kruger S et al. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 1998; 140: 25-30.
7. Muhlestein JB, Hammond EH, Carlquist JF et al. Increased incidence of Chlamydia species within the coronary artery of patients with symptomatic atherosclerotic versus other form of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.
8. Moazed TC, Kuo CC, Grayston IT et al. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998; 177: 1322-5.
9. Redecke V, DalhoffK, Bohnet S et al. Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am J Respir. Cell Mol Biol 1998; 19: 721-7.
10. May AE, Redecke V, Grüner S et al. Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice. Arterioscler Thromb Vasc Biol 2003; 23: 789-94.
11. Vehmaan-Kreula P, Puolakkainen M, Sarvas M et al. Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte- derived macrophages. Arterioscler Thromb Vasc Biol 2001; 21: 1-8.
12. Choi EY, Kim D, Hong BK et al. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: The potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis. Exp Mol Med 2002; 34: 391-400.
13. Ezzahiri R, Stassen FR, Kurvers HA et al. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc Surg 2003; 26: 88-95.
14. Galis ZS, Khatri J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
15. May AE, Kanse SM, Chavakis T et al. Molecular interactions between the urokinase receptor and integrins in the vasculature. Fibrinol Proteol 1998: 12: 205-12.
16. Belkin AM, Akimov SS, Zaritskaya LS et al. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem 2001; 276: 8415-22.
17. Caudroy S, Polette M, Nawrocki-Raby B et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002; 19: 697-702.
18. Major TC, Liang L, Xiaokong L et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002; 22: 1200-7.
19. Da Costa CU, Wantia N, Kirschning CJ et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. Eur J Immunol 2004; 34: 2874-84.
20. Ziegler-Heitbrock HW, Thiel E, Futterer A et al. Establishment of a human cell line (MonoMac 6) with characteristics of mature monocytes. Int. J Cancer 1988; 41: 456-61.
21. May AE, Kalsch T, Massberg S et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106: 2111-7.
22. May AE, Kanse SM, Lund LR et al. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 1998; 188: 1029-37.
23. May AE, Schmidt R, Kanse SM et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002; 100: 3611-7.
24. Barille S, Bataille R, Rapp MJ et al. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999; 163: 5723-8.
25. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003; 94: 569-74.
26. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621-8.
27. Kol A, Sukhova GK, Lichtman AH et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.
28. Netea MG, Selzman CH, Kullberg BJ et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur. J. Immunol 2000; 30: 541-9.
29. Haug C, Lenz C, Diaz F et al. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase Inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 1823-9.
30. Dechend R, Maass M, Gieffer J et al. Chlamydia pnumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappa B and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation 1999; 100: 1369-73.
31. Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, Maass M. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation. 2003; 108: 261-5.
32. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 29: 983-6.
33. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-53.
34. Bulut Y, Faure E, Thomas L et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168: 1435-40.
35. Costa CP, Kirschning CJ, Busch D et al. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol 2002; 32: 2460-70.
36. Kalayoglu MV, Indrawati, Morrison RP et al. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 2000; 181: 483-9.
37. Krull M, Maass M, Suttorp N et al. Chlamydophila pneumoniae. Mechanisms of target cell infection and activation. Thromb Haemost 2005; 94: 319-26.
38. Cannon CP, Braunwald E, McCabe CH et al., Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-54.
39. Grayston JT, Kronmal RA, Jackson LA et al., ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45.
40. Gieffers J, Füllgraf H., Jahn J et al.: Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001; 103: 351-6.